Is China Medicine Corp halal to invest in?

According to Musaffa's Shariah screening methodology, China Medicine Corp (CHME) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is China Medicine Corp a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes China Medicine Corp using these criteria to determine its compliance status.

Can Muslims buy shares of China Medicine Corp?

Muslim investors may consider investing in China Medicine Corp if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is China Medicine Corp classified as NOT COVERED?

Musaffa determines the Shariah status of China Medicine Corp by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for China Medicine Corp updated?

The Shariah compliance status of China Medicine Corp may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like China Medicine Corp become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of China Medicine Corp?

You can check the latest Shariah compliance status of China Medicine Corp on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

China Medicine Corp. Stock Analysis CHME

United States Health Care Nano Cap

China Medicine Corp. engages in the development, manufacture, and sale of western pharmaceuticals, traditional Chinese medicines, and other healthcare products. The company is headquartered in Guangzhou, Guangdong and currently employs 281 full-time employees. The company went IPO on 2005-06-23. The firm is engaged in the production and distribution of prescription and over the counter (OTC) drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The firm is developing a number of products for a range of indications, including oncology, high blood pressure and the removal of toxins from food and animal feeds. The firm's products include Shuangdan Capsules, Houerhuan Anti-inflammatory Capsules, Shugan Yipi Granules, Danggui Tiaojing Granules, Huangzao Granules, Pingfeng Shengmai Capsules, Danqi Tablets and Naodesheng Tablets. The firm also offers a range of dietary supplements, which include BeThin Tablets, Refrelizer Herbal Tea, LifeFull Herbal Tea and Relaxetox Herbal Tea. Shuangdan Capsules are indicated for the treatment of stagnation of the heart blood, obstruction of qi in the chest and cardiodynia.

Key Statistics of China Medicine Corp (CHME)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.02$0.02

Today's Open

$0.02

Volume

100.00K

P/E Ratio (TTM)

0.32

52 Week Range

$0.00$0.04

Market Cap

476.00K

Avg. Volume